| 摘要 |
Disclosed are single nucleotide polymorphisms (SMPs) associated with end stage renal disease. Also disclosed are methods for using SMPs to determine susceptibility to end stage renal disease; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs. |
